0000899243-18-006002.txt : 20180301 0000899243-18-006002.hdr.sgml : 20180301 20180301204917 ACCESSION NUMBER: 0000899243-18-006002 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180227 FILED AS OF DATE: 20180301 DATE AS OF CHANGE: 20180301 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: El-Hibri Fuad CENTRAL INDEX KEY: 0001380185 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33137 FILM NUMBER: 18659772 MAIL ADDRESS: STREET 1: 2273 RESEARCH BLVD, SUITE 400 CITY: ROCKVILLE STATE: MD ZIP: 20850 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Emergent BioSolutions Inc. CENTRAL INDEX KEY: 0001367644 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 141902018 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 PROFESSIONAL DR, SUITE 400 CITY: GAITHERSBURG STATE: MD ZIP: 20879 BUSINESS PHONE: 240-631-3200 MAIL ADDRESS: STREET 1: 400 PROFESSIONAL DR, SUITE 400 CITY: GAITHERSBURG STATE: MD ZIP: 20879 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-02-27 0 0001367644 Emergent BioSolutions Inc. EBS 0001380185 El-Hibri Fuad 400 PROFESSIONAL DRIVE, SUITE 400 GAITHERSBURG MD 20879 1 1 1 0 Chairman Common Stock 2018-02-27 4 M 0 9794 A 1540010 D Common Stock 2018-02-27 4 F 0 2385 49.64 D 1537625 D Common Stock 2018-02-28 4 M 0 9723 A 1547348 D Common Stock 2018-02-28 4 F 0 2368 49.97 D 1544980 D Common Stock 4344250 I By Intervac, L.L.C. Common Stock 1524155 I By Biovac, L.L.C. Restrictive Stock Units 2018-02-27 4 A 0 19288 0.00 A Common Stock 19288 81352 D Employee Stock Options (Right to Buy) 49.64 2018-02-27 4 A 0 38577 0.00 A 2025-02-26 Common Stock 38577 38577 D Restrictive Stock Units 2018-02-27 4 M 0 9794 0.00 D Common Stock 9794 71558 D Restrictive Stock Units 2018-02-28 4 M 0 9723 0.00 D Common Stock 9723 61835 D Restricted stock units convert into common stock on a one-for-one basis. Mr. El-Hibri's wife, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 40.65% equity interest in Intervac, L.L.C., which in turn is the direct owner of 4,344,250 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Intervac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein. Mr. El-Hibri, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 89.2% equity interest in Biovac, L.L.C, which in turn is the direct owner of 1,524,155 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Biovac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein. On February 27, 2018, Mr. El-Hibri was granted 19,288 restricted stock units vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. On February 27, 2018, Mr. El-Hibri was granted 38,577 stock options vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. On February 28, 2017, Mr. El-Hibri was granted 29,382 restricted stock units vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. On March 1, 2016, Mr. El-Hibri was granted 29,167 restricted stock units (after giving effect to the adjustment in connection with the Issuer's spin-off of Aptevo Therapeutics Inc.) vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. /s/ Carl A. Valenstein, attorney-in-fact 2018-03-01